AU2017331444B2 - Intracameral drug delivery depots - Google Patents

Intracameral drug delivery depots Download PDF

Info

Publication number
AU2017331444B2
AU2017331444B2 AU2017331444A AU2017331444A AU2017331444B2 AU 2017331444 B2 AU2017331444 B2 AU 2017331444B2 AU 2017331444 A AU2017331444 A AU 2017331444A AU 2017331444 A AU2017331444 A AU 2017331444A AU 2017331444 B2 AU2017331444 B2 AU 2017331444B2
Authority
AU
Australia
Prior art keywords
depot
depot composition
hydrogel
eye
travoprost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017331444A
Other languages
English (en)
Other versions
AU2017331444A1 (en
Inventor
Charles D. Blizzard
Ankita Darshan Desai
Arthur Driscoll
Peter Jarrett
Amarpreet S. Sawhney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incept LLC
Original Assignee
Incept LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incept LLC filed Critical Incept LLC
Publication of AU2017331444A1 publication Critical patent/AU2017331444A1/en
Application granted granted Critical
Publication of AU2017331444B2 publication Critical patent/AU2017331444B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017331444A 2016-09-23 2017-09-25 Intracameral drug delivery depots Active AU2017331444B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662398985P 2016-09-23 2016-09-23
US62/398,985 2016-09-23
PCT/US2017/053271 WO2018058048A1 (en) 2016-09-23 2017-09-25 Intracameral drug delivery depots

Publications (2)

Publication Number Publication Date
AU2017331444A1 AU2017331444A1 (en) 2019-04-18
AU2017331444B2 true AU2017331444B2 (en) 2023-08-17

Family

ID=60022215

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017331444A Active AU2017331444B2 (en) 2016-09-23 2017-09-25 Intracameral drug delivery depots

Country Status (11)

Country Link
US (3) US12171869B2 (enExample)
EP (2) EP4197527A1 (enExample)
JP (2) JP7430529B2 (enExample)
KR (3) KR102814241B1 (enExample)
CN (1) CN109982683A (enExample)
AU (1) AU2017331444B2 (enExample)
CA (1) CA3038075A1 (enExample)
DK (1) DK3515406T3 (enExample)
ES (1) ES2989941T3 (enExample)
IL (1) IL265421B2 (enExample)
WO (1) WO2018058048A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
EP4197527A1 (en) 2016-09-23 2023-06-21 Incept, LLC Intracameral drug delivery depots
CA3133172A1 (en) * 2019-03-13 2020-09-17 Susmita Bose Enzyme-degradable hydrogel for delivery of a payload
US20200337990A1 (en) * 2019-04-25 2020-10-29 Ocular Therapeutix, Inc. Hydrogel implants for lowering intraocular pressure
AU2020262932B2 (en) * 2019-04-25 2025-11-13 Ocular Therapeutix, Inc. Intracanalicular hydrogel inserts for the delivery of anesthetics
CN120346152A (zh) * 2019-04-25 2025-07-22 视尔普斯眼科公司 眼用水凝胶酪氨酸激酶抑制剂植入物
PT3861985T (pt) 2020-02-06 2023-08-03 Ocular Therapeutix Inc Composições e métodos para tratar doenças oculares
ES2952677T3 (es) * 2020-03-25 2023-11-03 Ocular Therapeutix Inc Implante ocular que contiene un inhibidor de tirosina cinasa
WO2021222117A1 (en) 2020-04-27 2021-11-04 Ocular Therapeutix, Inc. Methods of treating allergic conjunctivitis
CN116133664A (zh) * 2020-07-16 2023-05-16 视觉治疗股份有限公司 含有糖皮质激素的眼部插入物
JP2023542939A (ja) * 2020-09-24 2023-10-12 オキュラ セラピューティクス，インコーポレイテッド ヒドロゲル及び活性薬剤を含む徐放性生分解性小管内挿入物
DK3973952T3 (da) 2020-09-24 2024-03-18 Ocular Therapeutix Inc Bionedbrydelige intrakanalikulære indsatser med vedvarende frigivelse omfattende en hydrogel og cyclosporin
US20220378612A1 (en) * 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
CN114748436B (zh) * 2022-05-30 2023-05-16 迪沙药业集团有限公司 一种硝苯地平组合物及其制备方法
CA3264199A1 (en) * 2022-08-12 2024-02-15 Ocular Therapeutix Inc ORGANOGELS FOR PROLONGED MEDICINE ADMINISTRATION, THEIR PREPARATION PROCESSES AND USE
CN115337453A (zh) * 2022-08-15 2022-11-15 珠海肤原生物科技有限公司 一种载有2-氧杂环庚烷酮的均聚物微球的医用无菌胶原蛋白产品的制备
WO2024191453A1 (en) * 2023-03-10 2024-09-19 Clearstream Technologies Limited Radiation spacer hydrogels, methods of forming, and methods of use
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209478A1 (en) * 2009-02-12 2010-08-19 Sawhney Amarpreet S Drug delivery through hydrogel plugs
WO2010111449A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2016094646A1 (en) * 2014-12-10 2016-06-16 Incept, Llc Hydrogel drug delivery implants

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3640741A (en) 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
DE2437629C3 (de) 1974-08-05 1978-09-21 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von unlöslichen in Wasser nur wenig quellbaren Polymerisaten von N-Vinyllactamen
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4741872A (en) 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US5160745A (en) 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
IL82834A (en) 1987-06-09 1990-11-05 Yissum Res Dev Co Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5304595A (en) 1988-11-21 1994-04-19 Collagen Corporation Collagen-polymer conjugates
IL90193A (en) 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
FR2657018A1 (fr) 1990-01-12 1991-07-19 Merck Sharp & Dohme Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US6371975B2 (en) 1998-11-06 2002-04-16 Neomend, Inc. Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
JP2001520979A (ja) 1997-10-27 2001-11-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 網膜傷の閉鎖のための方法及び医薬組成物
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US20050049578A1 (en) 2000-04-14 2005-03-03 Hosheng Tu Implantable ocular pump to reduce intraocular pressure
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
MXPA03007665A (es) 2001-02-26 2004-03-16 Univ Duke Polimeros dendriticos novedosos y sus usos biomedicos.
US6913765B2 (en) 2001-03-21 2005-07-05 Scimed Life Systems, Inc. Controlling resorption of bioresorbable medical implant material
US20040131582A1 (en) 2002-02-26 2004-07-08 Grinstaff Mark W. Novel dendritic polymers and their biomedical uses
US20040024345A1 (en) 2002-04-19 2004-02-05 Morteza Gharib Glaucoma implant with valveless flow bias
US7351430B2 (en) 2002-11-06 2008-04-01 Uluru Inc. Shape-retentive hydrogel particle aggregates and their uses
US20040137059A1 (en) 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US7129210B2 (en) 2003-07-23 2006-10-31 Covalent Medical, Inc. Tissue adhesive sealant
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
WO2006031358A2 (en) 2004-08-13 2006-03-23 Hyperbranch Medical Technology, Inc. Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses
WO2006031388A2 (en) 2004-08-20 2006-03-23 Hyperbranch Medical Technology, Inc. Dentritic polymers, crosslinked gels, and their uses in orthopedic applications
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2007001926A2 (en) 2005-06-24 2007-01-04 Hyperbranch Medical Technology, Inc. Low-swelling hydrogel sealants for wound repair
WO2007005249A2 (en) 2005-06-29 2007-01-11 Hyperbranch Medical Technology, Inc. Nanoparticles and dendritic-polymer-based hydrogels comprising them
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US8895508B2 (en) 2009-07-24 2014-11-25 Yasuhiki Tabata Methods for corneal endothelial proliferation using bFGF sustained-release gelatin hydrogel particles
US7856528B1 (en) 2009-08-11 2010-12-21 Texas Memory Systems, Inc. Method and apparatus for protecting data using variable size page stripes in a FLASH-based storage system
JP5820815B2 (ja) 2009-12-15 2015-11-24 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ インプラントおよび生体分解性基準マーカー
DK3085358T3 (en) 2010-01-22 2018-02-05 Allergan Inc INTRAKAMERAL IMPLANTS WITH DEPOT PREPARATION
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
CN102905688B (zh) 2010-04-06 2015-11-25 阿勒根公司 用于前房内药物递送的缓释储库式植入物
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US10226417B2 (en) * 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CN109200013A (zh) 2011-12-05 2019-01-15 因赛普特有限责任公司 医用有机凝胶方法和组合物
WO2014120866A1 (en) 2013-01-31 2014-08-07 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure or glaucoma
CA2939952C (en) 2013-03-05 2022-03-22 Morgan V. Fedorchak Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery
BR112015022161B1 (pt) 2013-03-15 2020-11-24 Allergan, Inc Implante intraocular biodegradavel, uso do mesmo e metodo para fazer o mesmo
AU2014248460B2 (en) 2013-04-01 2019-04-11 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
JP6546194B2 (ja) 2013-12-06 2019-07-17 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼性状態を処置するための前房内インプラント
BR112018010671A8 (pt) 2015-11-25 2019-02-26 Incept Llc dispositivos e métodos de distribuição de fármaco com mudança de forma
EP4197527A1 (en) 2016-09-23 2023-06-21 Incept, LLC Intracameral drug delivery depots

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209478A1 (en) * 2009-02-12 2010-08-19 Sawhney Amarpreet S Drug delivery through hydrogel plugs
WO2010111449A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2016094646A1 (en) * 2014-12-10 2016-06-16 Incept, Llc Hydrogel drug delivery implants

Also Published As

Publication number Publication date
IL265421A (en) 2019-05-30
KR20240051303A (ko) 2024-04-19
JP7486539B2 (ja) 2024-05-17
IL265421B1 (en) 2023-12-01
ES2989941T3 (es) 2024-11-28
KR20230053707A (ko) 2023-04-21
CA3038075A1 (en) 2018-03-29
KR20190057353A (ko) 2019-05-28
US20250144012A1 (en) 2025-05-08
US20220401356A1 (en) 2022-12-22
DK3515406T3 (da) 2024-10-14
US12171869B2 (en) 2024-12-24
WO2018058048A1 (en) 2018-03-29
JP7430529B2 (ja) 2024-02-13
US20180085307A1 (en) 2018-03-29
CN109982683A (zh) 2019-07-05
JP2019529455A (ja) 2019-10-17
KR102814241B1 (ko) 2025-05-29
EP3515406A1 (en) 2019-07-31
KR102520771B1 (ko) 2023-04-12
EP4197527A1 (en) 2023-06-21
EP3515406B1 (en) 2024-07-24
IL265421B2 (en) 2024-04-01
BR112019005594A2 (pt) 2019-08-13
JP2022091998A (ja) 2022-06-21
AU2017331444A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
US20250144012A1 (en) Intracameral drug delivery depots
JP7256226B2 (ja) ハイドロゲルからの薬物送達
KR102039468B1 (ko) 의료용 유기젤 방법 및 조성물
EP3229779B1 (en) Hydrogel drug delivery implants
BR112019005594B1 (pt) Composição de depósito intracameral e uso da mesma para tratamento de uma condição ocular
BR122024018825A2 (pt) Composição de depósito e uso da mesma para tratamento de uma condição ocular
HK1252836B (en) Drug delivery from hydrogels

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)